drugset / Trial / NCT03740334

Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

NCT03740334

Phase 1 Active not recruiting 45 enrolled Dana-Farber Cancer Institute Novartis · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This research study is evaluating a drug called ribociclib (LEE011) given in combination with everolimus and other standard of care chemotherapy drugs as a possible treatment for relapsed or refractory ALL. The names of the drugs involved in this study are: * ribociclib * everolimus * dexamethasone

Timeline

Start
2019-01-30
Primary completion
2023-03-04
Completion
2026-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule
Subject Ribociclib Small molecule
Background Dexamethasone Small molecule Intravenous